Evidence map›Paper›PMID 31262738›Full record

ArticleBlood advances2019

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Arnon Nagler, Myriam Labopin, Bhagirathbhai Dholaria, Riitta Niittyvuopio, Johan Maertens, Xavier Poiré, Jan Cornelissen, Péter Reményi, Jean Henri Bourhis, Yves Beguin and 5 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 6 countries.

Arnon NaglerChaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
Myriam LabopinDepartment of Haematology and EBMT Paris study office/CEREST-TC, Saint Antoine Hospital, Paris, France.
Bhagirathbhai DholariaDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0003-2371-3655
Riitta NiittyvuopioStem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland.
Johan MaertensDepartment of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.ORCID 0000-0003-4257-5980
Xavier PoiréDepartment of Haematology, Cliniques Universitaires St. Luc, Brussels, Belgium.
Jan CornelissenDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Péter ReményiDepartment Haematology and Stem Cell Transplant, Dél-pesti Centrumkórház-Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary.
Jean Henri BourhisBone Marrow Transplantation Service, Department of Hematology, Institut de Cancérologie, Gustave Roussy, Villejuif, France.
Yves BeguinDepartment of Hematology, University of Liege, Centre Hospitalier Universitaire Sart-Tilman, Liege, Belgium.
Ram MalladiDepartment of Haematology, Queen Elizabeth Medical Centre, Edgbaston, University Hospital Birmingham National Health Service Trust, Birmingham, United Kingdom.
Tessa KerreDepartment of Haematology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-2114-2844
Wilfried SchroyensDepartment of Hematology, Antwerp University Hospital, Antwerp Edegem, Belgium.
Bipin N SavaniStem Cell Transplant Processing Laboratory, Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN; and.
Mohamad MohtyDepartment of Haematology and EBMT Paris study office/CEREST-TC, Saint Antoine Hospital, INSERM UMR 938 and Université Pierre et Marie Curie, Paris, France.
Vanderbilt University Medical Center · USAntwerp University Hospital · BECliniques Universitaires Saint-Luc · BEErasmus MC Cancer Institute · NLGhent University Hospital · BEHôpital Saint-Antoine · FRInserm · FRInstitut Gustave Roussy · FRNational Health Service · GBTel Aviv University · ILUniversitair Ziekenhuis Leuven · BEUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of the use of antithymocyte globulin (ATG) following a total body irradiation (TBI)-based myeloablative conditioning regimen has been poorly explored. We retrospectively analyzed 724 patients who underwent a first allogeneic hematopoietic cell transplantation (allo-HCT) following a TBI-based conditioning regimen for acute myeloid leukemia (AML) and compared the outcomes of 251 (35%) patients who received ATG (ATG group) with 473 (65%) patients who did not (non-ATG group). Median follow-up of surviving patients was 59 months (interquartile range, 28-83). The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) for non-ATG and ATG groups in the first 100 days was 33% vs 24%, respectively (

Indexed as

Transplantation ConditioningWhole-Body IrradiationAdultAgedAged, 80 and overAntilymphocyte SerumFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesTransplantation, HomologousAntilymphocyte Serum

Identifiers

PMID31262738
PMCPMC6616257
OpenAlexW2955170583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.